Immunocellular OTC Stock Probability of Future OTC Stock Price Finishing Over 0.65

IMUC -  USA Stock  

USD 0.65  0.01  1.52%

Immunocellular Therapeutics' future price is the expected price of Immunocellular Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Immunocellular Therapeutics performance during a given time horizon utilizing its historical volatility.

Immunocellular Price Probability 

 
Refresh
Please see Immunocellular Therapeutics Backtesting, Immunocellular Therapeutics Valuation, Immunocellular Therapeutics Correlation, Immunocellular Therapeutics Hype Analysis, Immunocellular Therapeutics Volatility, Immunocellular Therapeutics History as well as Immunocellular Therapeutics Performance. Please specify Immunocellular Therapeutics time horizon, a valid symbol (red box) and a target price (blue box) you would like Immunocellular Therapeutics odds to be computed.
Apply Odds

Immunocellular Therapeutics Target Price Odds to finish over 0.65

The tendency of Immunocellular OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for foresting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.65 90 days 0.65  about 5.52
Based on a normal probability distribution, the odds of Immunocellular Therapeutics to move above the current price in 90 days from now is about 5.52 (This Immunocellular Therapeutics probability density function shows the probability of Immunocellular OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Immunocellular Therapeutics has a beta of -0.13. This usually indicates as returns on benchmark increase, returns on holding Immunocellular Therapeutics are expected to decrease at a much lower rate. During the bear market, however, Immunocellular Therapeutics is likely to outperform the market. In addition to that The company has an alpha of 2.1469, implying that it can generate a 2.15 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Immunocellular Therapeutics Price Density 
      Price 

Predictive Modules for Immunocellular Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immunocellular Therapeutics. Regardless of method or technology, however, to accurately forecast the stock or bond market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Immunocellular Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Immunocellular Therapeutics in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
0.030.5219.45
Details
Intrinsic
Valuation
LowReal ValueHigh
0.020.4319.36
Details
Naive
Forecast
LowNext ValueHigh
0.0142280.7119.64
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.560.620.68
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Immunocellular Therapeutics. Your research has to be compared to or analyzed against Immunocellular Therapeutics' peers to derive any actionable benefits. When done correctly, Immunocellular Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Immunocellular Therapeutics.

Immunocellular Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Immunocellular Therapeutics is not an exception. The market had few large corrections towards the Immunocellular Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immunocellular Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immunocellular Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over DOW
2.15
β
Beta against DOW-0.13
σ
Overall volatility
0.09
Ir
Information ratio 0.11

Immunocellular Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immunocellular Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immunocellular Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Immunocellular Therapeutics is way too risky over 90 days horizon
Immunocellular Therapeutics has some characteristics of a very speculative penny stock
Immunocellular Therapeutics appears to be risky and price may revert if volatility continues
Immunocellular Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 300 K. Net Loss for the year was (9.03 M) with profit before overhead, payroll, taxes, and interest of 0.
Immunocellular Therapeutics currently holds about 2.85 M in cash with (10.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.equities.com: Sorrento falls 1.82 percent for October 8 - Equities.com

Immunocellular Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immunocellular OTC Stock often depends not only on the future outlook of the current and potential Immunocellular Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immunocellular Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Shares Percent Shares Out3.96%
Short Percent Of Float3.96%
Float Shares4.18M
Shares Short Prior Month147.78k
Average Daily Volume Last 10 Day26.77k
Average Daily Volume In Three Month9.14k
Date Short Interest15th of October 2018

Immunocellular Therapeutics Technical Analysis

Immunocellular Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Immunocellular OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Immunocellular Therapeutics. In general, you should focus on analyzing Immunocellular OTC Stock price patterns and their correlations with different microeconomic environments and drivers.

Immunocellular Therapeutics Predictive Forecast Models

Immunocellular Therapeutics time-series forecasting models is one of many Immunocellular Therapeutics' otc stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunocellular Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Immunocellular Therapeutics

Checking the ongoing alerts about Immunocellular Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Immunocellular Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Immunocellular Therapeutics Alerts

Immunocellular Therapeutics Alerts and Suggestions

Immunocellular Therapeutics is way too risky over 90 days horizon
Immunocellular Therapeutics has some characteristics of a very speculative penny stock
Immunocellular Therapeutics appears to be risky and price may revert if volatility continues
Immunocellular Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 300 K. Net Loss for the year was (9.03 M) with profit before overhead, payroll, taxes, and interest of 0.
Immunocellular Therapeutics currently holds about 2.85 M in cash with (10.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.equities.com: Sorrento falls 1.82 percent for October 8 - Equities.com
Please see Immunocellular Therapeutics Backtesting, Immunocellular Therapeutics Valuation, Immunocellular Therapeutics Correlation, Immunocellular Therapeutics Hype Analysis, Immunocellular Therapeutics Volatility, Immunocellular Therapeutics History as well as Immunocellular Therapeutics Performance. Note that the Immunocellular Therapeutics information on this page should be used as a complementary analysis to other Immunocellular Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Immunocellular OTC Stock analysis

When running Immunocellular Therapeutics price analysis, check to measure Immunocellular Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocellular Therapeutics is operating at the current time. Most of Immunocellular Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immunocellular Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunocellular Therapeutics' price. Additionally, you may evaluate how the addition of Immunocellular Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
The market value of Immunocellular Therapeutics is measured differently than its book value, which is the value of Immunocellular that is recorded on the company's balance sheet. Investors also form their own opinion of Immunocellular Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immunocellular Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunocellular Therapeutics' market value can be influenced by many factors that don't directly affect Immunocellular Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunocellular Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunocellular Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunocellular Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.